Small-molecule inhibition of γ-glutamyl carboxylase reveals a novel anticoagulant strategy
Oral anticoagulants such as warfarin, which function as vitamin K antagonists (VKAs), have long been central to anticoagulation therapy. Warfarin inhibits vitamin K epoxide reductase (VKOR), thus restricting the availability of reduced vitamin K and impairing the γ-carboxylation and activation of vitamin K-dependent clotting factors (VKDCFs). However, warfarin's clinical use is hindered by a narrow therapeutic index and marked interindividual variability, largely attributable to genetic variation in VKOR, yet it remains the only oral anticoagulant option for clinical conditions like antiphospholipid antibody syndrome. γ-Glutamyl carboxylase (GGCX), the enzyme that directly modifies VKDCFs, represents an attractive yet largely unexplored target for anticoagulation. Through a cell-based high-throughput screen of the Maybridge Hit-Finder compound library (comprising 14,400 drug-like molecules), we identified 21 compounds that inhibited γ-carboxylation of VKDCFs. Subsequent gene-deficient cell-based assays and in vitro enzymatic characterization revealed that compound HF13141-H5 selectively and potently inhibits GGCX activity, with nanomolar half-maximal inhibitory concentrations. Molecular docking with the recently resolved GGCX structure suggested that HF13141-H5 mimics the binding of reduced vitamin K, and site-directed mutagenesis confirmed the critical hydrogen bond with residue N290 within the substrate-binding pocket. Importantly, HF13141-H5 maintained full inhibitory potency against VKOR variants associated with warfarin resistance and demonstrated robust anticoagulant activity in a zebrafish laser-induced endothelial injury model. In summary, we describe the discovery and mechanistic characterization of HF13141-H5 as the first small-molecule GGCX inhibitor. By directly targeting GGCX, HF13141-H5 presents a promising strategy for developing next-generation anticoagulants that could overcome the limitations of warfarin, including genetic variability and resistance.
Authors
- Qing Cao (ORCID: https://orcid.org/0000-0002-1523-8797)
- Catherine E. Richter (ORCID: https://orcid.org/0000-0001-9377-5267)
- Jordan A. Shavit (ORCID: https://orcid.org/0000-0002-2874-4904)
- Shixia Dong
- Yan Shen (ORCID: https://orcid.org/0000-0001-7058-8602)
- H. L. Liu
- Dan Song (ORCID: https://orcid.org/0000-0002-8764-7610)
- Zhenyu Hao (ORCID: https://orcid.org/0000-0001-6418-2921)
- S Li
- Xuejie Chen
- DW Stafford
- Jian-Ke Tie
- Yiming Guo
- Guomin Shen
Institutions
- University of North Carolina at Chapel Hill (US)
- Harbin Medical University (CN)
- Henan University of Science and Technology (CN)
- University of Michigan (US)
- Michigan United (US)
- Second Affiliated Hospital of Harbin Medical University (CN)
- Yangzhou Vocational University (CN)
- Yangzhou University (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Blood Advances
- Published
- 2025-12-22
- DOI
- https://doi.org/10.1182/bloodadvances.2025018776
- Primary Topic
- Vitamin K Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Government of Jiangsu Province
- Natural Science Foundation of Jiangsu Province
- National Institutes of Health
- McDonnell Center for Systems Neuroscience